Management of pharmacotherapy‐related problems in acute coronary syndrome: Role of clinical pharmacist in cardiac rehabilitation unit
- 9 February 2019
- journal article
- research article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 125 (1) , 44-53
Abstract
Acute coronary syndrome (ACS) is one of the leading causes of mortality worldwide and negatively impacts healthcare costs, productivity and quality of life. Polymorbidity and polypharmacy predispose ACS patients to medication discrepancies between cardiologist‐prescribed medication and drug use by the patient, drug‐related problems (DRPs) and inadequate drug adherence. This study aimed to evaluate the impact of clinical pharmacist–provided services on the outcome of ACS patients. This was a prospective, randomized, controlled study on ACS patients participating in a cardiac rehabilitation programme. Forty ACS patients were randomly assigned to either control group, who received standard medical care, or intervention group, who received standard medical care plus clinical pharmacist–provided services. Services included DRP management, clinical assessment and enforcing the patient education and adherence. For both groups, the following were assessed at baseline and after 3 months: DRPs, adherence (assessed by 8‐item Morisky Adherence Questionnaire), patient's knowledge (assessed by Coronary Artery Disease Questionnaire), 36‐Short Form Health Survey (SF‐36), heart rate, systolic and diastolic blood pressure, low‐density lipoprotein (LDL), total cholesterol (TC) and fasting blood glucose (FBG). After 3 months, there was a significant difference between the intervention and control groups in the per cent change of DRPs (median: −100 vs 5.882, P = 0.0001), patient's adherence score (median: 39.13 vs −14.58, P = 0.0001), knowledge score (median: 30.28 vs −5.196, P = 0.0001), SF‐36 scores, heart rate (mean: −10.04 vs 6.791, P = 0.0001), diastolic blood pressure (mean: −17.87 vs 10.45, P = 0.0001), systolic blood pressure (mean: −16.22 vs 4.751, P = 0.0001), LDL (median: −25.73 vs −0.2538, P = 0.0071), TC (median: −14.62 vs 4.123, P = 0.0005) and FBG (median: −11.42 vs 5.422, P = 0.0098). Clinical pharmacists can play an important role as part of a cardiac rehabilitation team through patient education and interventions to minimize DRPs.Keywords
This publication has 35 references indexed in Scilit:
- The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon dischargeJournal of Clinical Pharmacy and Therapeutics, 2013
- Patient-focused intervention to improve long-term adherence to evidence-based medications: A randomized trialAmerican Heart Journal, 2012
- Handling drug-related problems in rehabilitation patients: a randomized studyInternational Journal of Clinical Pharmacy, 2012
- Development and validation of an English version of the Coronary Artery Disease Education Questionnaire (CADE‐Q)European Journal of Preventive Cardiology, 2012
- ACC 2009 Survey Results and Recommendations: Addressing the Cardiology Workforce CrisisJACC, 2009
- Medication AdherenceCirculation, 2009
- Awareness of risk factors for coronary heart disease following interventional cardiology procedures: A key concern for nursing practiceInternational Journal of Nursing Practice, 2008
- The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart diseaseFamily Practice, 2007
- Pharmacist‐Led Cardiac Risk Reduction ModelPreventive Cardiology, 2006
- Drug-Related Problems in Hospitalised PatientsDrug Safety, 2000